The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Prostate-Specific Antigen and Pain Surrogacy Analysis in Metastatic Hormone-Refractory Prostate Cancer
Abstract
Purpose: It is currently unclear if early prostate-specific antigen (PSA) or pain improvements are adequate surrogates for overall survival in men with metastatic hormone-refractory prostate cancer (HRPC). Here we examined various degrees of PSA decline and pain response as surrogates for the survival benefit observed in the TAX327 trial. Patients and Methods: In the TAX327 trial, 1,006 men with HRPC were randomly assigned to receive docetaxel in two schedules, or mitoxantrone, each with prednisone: 989 men provided data on 3-month PSA decline. Surrogacy was examined for post-treatment changes in PSA and pain response using Cox proportional hazards models to calculate the proportion of treatment effect (PTE) explained by each potential surrogate. Results: A ≥ 30% PSA decline within 3 months of treatment initiation provides the highest degree of surrogacy, with a PTE of 0.66 (95% CI, 0.23 to 1.0), and was associated with a hazard ratio (HR) of 0.50 (95% CI, 0.43 to 0.58) for overall survival after adjusting for treatment effect. Introduction of a ≥ 30% PSA decline is predictive of survival regardless of treatment arm. Other changes in PSA or PSA kinetics, PSA normalization, and pain responses were highly prognostic but weaker surrogates for survival. Conclusion: In the TAX327 trial, a PSA decline of ≥ 30% within 3 months of chemotherapy initiation had the highest degree of surrogacy for overall survival, confirming data from the Southwest Oncology Group 9916 trial. However, given the wide CIs around the estimate of this moderate surrogate effect, overall survival should remain the preferred end point for phase III trials of cytotoxic agents in HRPC.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Jemal, A., Siegel, R., Ward, E., Murray, T., Xu, J., & Thun, M. J. (2007) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.57.1.43 · Cited by 7,439
The McGill Pain Questionnaire: Major properties and scoring methods
Melzack, R. (1975) · Pain · doi:10.1016/0304-3959(75)90044-5 · Cited by 6,845
A note on a general definition of the coefficient of determination
NAGELKERKE, N. J. D. (1991) · Biometrika · doi:10.1093/biomet/78.3.691 · Cited by 5,927
Docetaxel plus Prednisone or Mitoxantrone plus Prednisone for Advanced Prostate Cancer
Tannock, I. F., de Wit, R., Berry, W. R., Horti, J., Pluzanska, A., Chi, K. N., Oudard, S., Théodore, C., James, N. D., Turesson, I., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040720 · Cited by 5,735
Self-citationPetrylak, D. P., Tangen, C. M., Hussain, M. H. A., Lara, P. N., Jones, J. A., Taplin, M. E., Burch, P. A., Berry, D., Moinpour, C., Kohli, M., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa041318 · Cited by 3,665
Surrogate endpoints in clinical trials: Definition and operational criteria
Prentice, R. L. (1989) · Statistics in Medicine · doi:10.1002/sim.4780080407 · Cited by 2,057
Bubley, G. J., Carducci, M., Dahut, W., Dawson, N., Daliani, D., Eisenberger, M., Figg, W. D., Freidlin, B., Halabi, S., Hudes, G., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.11.3461 · Cited by 977
Self-citationPrognostic Model for Predicting Survival in Men With Hormone-Refractory Metastatic Prostate Cancer
Halabi, S., Small, E. J., Kantoff, P. W., Kattan, M. W., Kaplan, E. B., Dawson, N. A., Levine, E. G., Blumenstein, B. A., & Vogelzang, N. J. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.06.100 · Cited by 674
Statistical validation of intermediate endpoints for chronic diseases
Freedman, L. S., Graubard, B. I., & Schatzkin, A. (1992) · Statistics in Medicine · doi:10.1002/sim.4780110204 · Cited by 651
ESTIMATING THE PROPORTION OF TREATMENT EFFECT EXPLAINED BY A SURROGATE MARKER
LIN, D. Y., FLEMING, T. R., & DE GRUTTOLA, V. (1997) · Statistics in Medicine · doi:10.1002/(sici)1097-0258(19970715)16:13<1515::aid-sim572>3.0.co;2-1 · Cited by 520
Smaletz, O., Scher, H. I., Small, E. J., Verbel, D. A., McMillan, A., Regan, K., Kelly, W. K., & Kattan, M. W. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.11.021 · Cited by 386
Kelly, W. K., Scher, H. I., Mazumdar, M., Vlamis, V, Schwartz, M., & Fossa, S. D. (1993) · Journal of Clinical Oncology · doi:10.1200/jco.1993.11.4.607 · Cited by 385
Evaluation of Prostate-Specific Antigen Declines for Surrogacy in Patients Treated on SWOG 99-16
Petrylak, D. P., Ankerst, D. P., Jiang, C. S., Tangen, C. M., Hussain, M. H. A., Lara, P. N., Jones, J. A., Taplin, M. E., Burch, P. A., Kohli, M., et al. (2006) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djj129 · Cited by 275
Smith, D. C., Dunn, R. L., Strawderman, M. S., & Pienta, K. J. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.5.1835 · Cited by 215
Scher, H. I., Kelly, W. M. K., Zhang, Z.-F., Ouyang, P., Sun, M., Schwartz, M., Ding, C., Wang, W., Horak, I. D., & Kremer, A. B. (1999) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/91.3.244 · Cited by 165
D'Amico, A. V., Moul, J. W., Carroll, P. R., Cote, K., Sun, L. L., Lubeck, D. P., Renshaw, A. A., Loffredo, M. J., & Chen, M. (2004) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djh086 · Cited by 34
Explained Variation in Proportional Hazards Regression
́Quigly, J. O. (2005) · Chapman & Hall/CRC eBooks · doi:10.1201/9781420027761-27 · Cited by 21
Cited by
Scher, H. I., Halabi, S., Tannock, I., Morris, M., Sternberg, C. N., Carducci, M. A., Eisenberger, M. A., Higano, C., Bubley, G. J., Dreicer, R., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.12.4487 · Cited by 2,241
Self-citationde Bono, J. S., Scher, H. I., Montgomery, R. B., Parker, C., Miller, M. C., Tissing, H., Doyle, G. V., Terstappen, L. W. W. M., Pienta, K. J., & Raghavan, D. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0872 · Cited by 2,182
Scher, H. I., Morris, M. J., Stadler, W. M., Higano, C., Basch, E., Fizazi, K., Antonarakis, E. S., Beer, T. M., Carducci, M. A., Chi, K. N., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.64.2702 · Cited by 1,654
Self-citationProstate-specific antigen and prostate cancer: prediction, detection and monitoring
Lilja, H., Ulmert, D., & Vickers, A. J. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2351 · Cited by 921
Attard, G., Reid, A. H. M., Yap, T. A., Raynaud, F., Dowsett, M., Settatree, S., Barrett, M., Parker, C., Martins, V., Folkerd, E., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.9749 · Cited by 903
Metadata
- Authors
- Armstrong, A. J., Garrett-Mayer, E., Ou Yang, Y.-C., Carducci, M. A., Tannock, I., de Wit, R., & Eisenberger, M.
- Venue
- Journal of Clinical Oncology
- Published
- 2007-09-01
- Volume
- 25
- Issue
- 25
- Pages
- 3965-3970
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2125942853
- Cited by
- 275
- References
- 17
- FWCI
- 19.01
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.